Demand and Trend Analysis of Alopecia Treatment in Asia Pacific
Study on Alopecia Treatment in Asia Pacific by Alopecia Areata, Alopecia Totalis, and Alopecia Universalis for Hospitals, Dermatology & Trichology Clinics, and Home Care Settings from 2024 to 2034
Analysis of Alopecia Treatment Industry Covering Countries Includes Analysis of Japan, China, India, Australia, New Zealand, Singapore, and South Korea
Alopecia Treatment Demand Outlook for Asia Pacific (2024 to 2034)
Sales of alopecia treatment products in Asia Pacific are estimated at US$ 2.66 billion for 2024 and are forecasted to increase at a CAGR of 6.6% to reach US$ 5.03 billion by the end of 2034.
Alopecia treatment refers to therapeutic interventions aimed at addressing hair loss or alopecia, which can occur due to various factors such as genetics, hormonal changes, autoimmune conditions, or environmental influences.
The market in Asia Pacific is witnessing healthy growth due to several factors, including growing awareness of alopecia and its treatment, technological advancements in drugs and therapies, and changing lifestyles. As per this new industry analysis by Fact.MR, a market research and competitive intelligence provider, cultural significance of healthy hair and availability of various treatment options are further contributing to the growing demand for alopecia treatment solutions.
- Increasing at a CAGR of 5.5%, sales of alopecia treatment drugs in East Asia are valued at US$ 1.97 billion in 2024 and are predicted to reach US$ 3.36 billion by 2034.
- Alopecia areata treatment drug sales in Asia Pacific are projected to increase at a CAGR of 6.6% and reach US$ 3.38 billion by 2034-end.
Alopecia areata is an autoimmune disorder characterized by the sudden loss of hair in defined patches on the scalp or other areas of the body. It occurs when the immune system mistakenly attacks the hair follicles, leading to hair loss. Severity and extent of hair loss can vary, ranging from small, round patches to total loss of hair on the scalp or body.
Incidence of alopecia areata is rising globally, including in the Asia Pacific region. This growing prevalence is subsequently leading to high demand for effective drug treatments across the region. Patients are increasingly seeking advanced and innovative treatments to address their specific needs.
Factors such as stress, environmental changes, and lifestyle choices are contributing to the increased onset or exacerbation of autoimmune conditions such as alopecia areata. Rapidly changing lifestyles in Asia Pacific are also fuelling the sales of pharmaceutical solutions for the treatment of alopecia areata.
| Report Attributes | Details |
|---|---|
| Alopecia Treatment Revenue in Asia Pacific (2024E) | US$ 2.66 Billion |
| Forecasted Sales (2034F) | US$ 5.03 Billion |
| Demand Growth (2024 to 2034) | 6.6% CAGR |
| Alopecia Areata Treatment Drug Sales (2024E) | US$ 1.78 Billion |
| Market Share of Aesthetic Clinics (2024) | 15% |
| Alopecia Totalis Drug Sales (2034F) | US$ 1.18 Billion |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Johnson & Johnson, Inc.; Dr. Reddy’s Laboratories Ltd.; Cipla Ltd.; Cellmid Ltd.; The Himalaya Drug Company; Taisho Pharmaceutical Holdings Co., Ltd.; Shiseido Co., Ltd.; Zhangguang 101 Science & Technology Co., Ltd. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is Asia Pacific a High-Growth Market for Alopecia Drug Manufacturers?
“Innovative Maneuvers Enhancing Alopecia Treatment Practices”
Alopecia treatment in Asia Pacific is witnessing a transformative phase marked by a surge in technological innovations in medical science, revolutionizing the market for hair loss solutions. These advancements are introducing more diverse and effective treatment modalities, catering to the evolving needs of individuals experiencing alopecia.
Cutting-edge laser therapies are gaining prominence in the region for their non-invasive approach to stimulating hair follicles. Low-level laser therapy (LLLT) is showing promising results in promoting hair growth, with devices ranging from laser combs to wearable caps becoming increasingly accessible to consumers.
Platelet-rich plasma (PRP) treatments are emerging as a popular and minimally invasive option in Asia Pacific. This innovative technique involves the extraction and injection of the patient's platelet-rich blood, promoting hair regrowth and improving the overall health of the scalp.
Introduction of novel pharmaceuticals, particularly JAK inhibitors such as LITFULO (Ritlecitinib), showcases a breakthrough in alopecia treatment. These medications target the immune system's response, addressing the underlying autoimmune nature of alopecia areata, and have gained approval for use in both adults and adolescents.
Advancements in topical solutions, including corticosteroid creams and other formulations, provide convenient options for individuals seeking localized treatment. These solutions aim to manage inflammation and stimulate hair regrowth with targeted applications. The amalgamation of these technological innovations not only enhances the efficacy of alopecia treatments in the Asia Pacific but also contributes to a shift in the perception of hair loss management.
“Growing Prevalence of Alopecia with Urban Modernity”
The relentless pace of modern life, characterized by hectic schedules, tight deadlines, and constant connectivity, is ushering in a new era of stress. Chronic stress, a known contributor to hair loss, is becoming more prevalent as individuals navigate the demands of fast-paced urban living.
Urban environments bring with them a myriad of environmental stressors, from pollution to harsh weather conditions. These external aggressors can adversely affect the health of the scalp and hair, exacerbating conditions including alopecia.
Changes in dietary patterns, marked by a growing reliance on processed foods and nutrient-deficient diets, play a role in the health of hair follicles. Poor nutrition can contribute to the onset or worsening of alopecia, making it imperative to address dietary factors in treatment strategies. As the tapestry of modern life continues to evolve, understanding and addressing the intricate interplay of these factors become paramount in developing comprehensive alopecia treatment strategies.
Which Aspects are Creating Trust Issues Among Asian Alopecia Patients?
“Adverse and Allergic Reactions Challenging Adoption of Alopecia Treatment Drugs”
While the market in Asia Pacific is on an upward trajectory, a looming concern casts a shadow on its growth, the potential side effects associated with alopecia drugs. These adverse effects are anticipated to be a significant hindrance to market expansion, posing challenges for both patients and the industry.
Many alopecia drugs, especially systemic medications, may come with a range of systemic side effects. These can include gastrointestinal disturbances, changes in blood cell counts, and immune system alterations, leading to concerns about overall health impacts.
Even seemingly innocuous topical treatments may not be exempt from drawbacks. Skin irritations, allergic reactions, or dermatitis are potential side effects that may deter individuals from consistent use, impacting the efficacy of the treatment. Negative side effects can impact the overall perception of alopecia treatments, eroding public trust.
“Strict Product Approval Policies Slowing Down Pace of New Product Offerings”
Stringent regulatory scrutiny, especially concerning potential side effects, may lead to delays in market approval or even rejection of certain drugs. This can impede the introduction of new and potentially more effective treatments.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
How is Appearance Consciousness Increasing Alopecia Treatment Drug Sales in China?
“Growing Awareness about Alopecia Treatment Primarily Increasing Consumption of Related Medications”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 961 Million |
| Growth Rate (2024 to 2034) | 5.7% CAGR |
| Projected Value (2034F) | US$ 1.67 Billion |
China's rapid economic development is having a positive influence on healthcare access and awareness. Rising disposable incomes and urbanization are contributing to a growing demand for alopecia treatment drugs as individuals become more conscious of their health and appearance.
- Statistics from the Belgravia Centre point to a noteworthy trend in China, revealing that approximately 21% of men grapple with genetic hair loss, whereas the corresponding figure for women hovers around 6%.
China is becoming a hub for medical tourism, attracting individuals seeking advanced alopecia treatments. This influx of patients is contributing to the sales of alopecia treatment drugs in the country.
Will Alopecia Drug Suppliers Be Profitable in Japan?
“Advancements in Healthcare Sector Leading to Production of Innovative Alopecia Drugs for All Age Groups”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 874 Million |
| Growth Rate (2024 to 2034) | 5.4% CAGR |
| Projected Value (2034F) | US$ 1.48 Billion |
Japan is known for its advanced research and development initiatives in the healthcare sector. This commitment to innovation results in the availability of cutting-edge alopecia treatment drugs, driving sales growth in the country.
Similar to China, Japan has a significant aging population. The prevalence of age-related hair loss concerns is also contributing to the consistent demand for effective alopecia treatment drugs.
How is Cosmetic Culture Having a Major Influence on Alopecia Drug Sales in South Korea?
“Aesthetic Culture and Alopecia Treatment Trends Huge in South Korea”
| Attribute | South Korea |
|---|---|
| Market Value (2024E) | US$ 130 Million |
| Growth Rate (2024 to 2034) | 5% CAGR |
| Projected Value (2034F) | US$ 210.4 Million |
South Korea's emphasis on beauty and aesthetics culture is significantly influencing the demand for alopecia treatment drugs. South Korean consumers seek effective solutions to address hair loss and maintain a youthful appearance.
South Korea is renowned for its innovations in the cosmetic industry. The integration of pharmaceutical solutions for alopecia within the broader cosmetic landscape amplifies the profitable market for treatment drugs.
Category-wise Analysis
Why Do Alopecia Patients Widely Prefer Dermatology and Trichology Clinics for Treatment?
“Presence of Specialized Expertise and Accurate Diagnostic Technologies”
| Attribute | Dermatology and Trichology Clinics |
|---|---|
| Segment Value (2024E) | US$ 1.12 Billion |
| Growth Rate (2024 to 2034) | 6.6% CAGR |
| Projected Value (2034F) | US$ 2.12 Billion |
Dermatology and trichology clinics are staffed with specialists who have specific expertise in diagnosing and treating hair and scalp conditions, including alopecia. Patients seeking solutions for hair loss are more likely to visit these clinics for specialized care.
Dermatologists and trichologists can accurately diagnose the type and cause of alopecia through thorough examinations, scalp analysis, and sometimes even biopsies. This precise diagnosis is crucial for determining the most effective treatment approach. Thus, demand for alopecia drugs is high in dermatology and trichology clinics due to the high patient visits, presence of specialized expertise, accurate diagnosis, customized treatment plans, and comprehensive care.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Alopecia drug suppliers in Asia Pacific are earning more by diversifying their product portfolios. Offering a range of drugs with different mechanisms of action, formulations, and delivery methods is helping suppliers cater to diverse patient needs. This is also aiding them in achieving high-profit shares.
Several alopecia drug manufacturers in the Asia Pacific are also engaging in strategic collaborations and partnerships with research institutions, healthcare providers, and other industry stakeholders. By working together, producers can accelerate drug development, streamline regulatory processes, and expand their market reach. This strategy is also enhancing efficiency and allowing for a more comprehensive approach to alopecia treatment.
- In 2021, Dr. Reddy’s Laboratories Ltd. unveiled an innovative medication tailored for addressing female pattern hair loss.
- In June 2023, the FDA approved Litfulo, Pfizer's ground-breaking oral treatment designed specifically for addressing alopecia in teenagers.
Segmentation of Alopecia Treatment Study in Asia Pacific
-
By Type :
- Alopecia Areata
- Alopecia Totalis
- Alopecia Universalis
-
By Treatment Type :
- Topical Drugs
- Oral Drugs
- Injectables
- Hair Transplant Services
- Low-level Laser Therapies
-
By End User :
- Hospitals
- Dermatology & Trichology Clinics
- Home Care Settings
- Aesthetic Clinics
-
By Country :
- Japan
- China
- India
- Australia
- New Zealand
- Singapore
- South Korea
Table of Content
- 1. Asia Pacific Industry - Executive Summary
- 2. Asia Pacific Industry Overview
- 3. Industry Risks and Trends Assessment
- 4. Industry Background and Data Points
- 5. Asia Pacific Industry Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 6. Asia Pacific Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
- 6.1. Alopecia Areata
- 6.2. Alopecia Totalis
- 6.3. Alopecia Universalis
- 7. Asia Pacific Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, by Treatment Type
- 7.1. Topical Drugs
- 7.2. Oral Drugs
- 7.3. Injectables
- 7.4. Hair Transplant Services
- 7.5. Low-level Laser Therapies
- 8. Asia Pacific Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, by End User
- 8.1. Hospitals
- 8.2. Dermatology & Trichology Clinics
- 8.3. Home Care Settings
- 8.4. Aesthetic Clinics
- 9. Asia Pacific Industry Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country
- 9.1. India
- 9.2. Singapore
- 9.3. Japan
- 9.4. China
- 9.5. Australia & New Zealand
- 9.6. South Korea
- 10. India Industry Analysis 2018 to 2023 and Forecast 2024 to 2034
- 11. Singapore Industry Analysis 2018 to 2023 and Forecast 2024 to 2034
- 12. Japan Industry Analysis 2018 to 2023 and Forecast 2024 to 2034
- 13. China Industry Analysis 2018 to 2023 and Forecast 2024 to 2034
- 14. Australia & New Zealand Industry Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. South Korea Industry Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. Industry Structure Analysis
- 17. Competition Analysis
- 17.1. Teva Pharmaceutical Industries Ltd.
- 17.2. Merck & Co., Inc.
- 17.3. Johnson & Johnson, Inc.
- 17.4. Dr. Reddy’s Laboratories Ltd.
- 17.5. Cipla Ltd.
- 17.6. Cellmid Ltd.
- 17.7. The Himalaya Drug Company
- 17.8. Taisho Pharmaceutical Holdings Co., Ltd.
- 17.9. Shiseido Co., Ltd.
- 17.10. Zhangguang 101 Science & Technology Co., Ltd.
- 18. Assumptions and Acronyms Used
- 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Asia Pacific Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 02: Asia Pacific Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 03: Asia Pacific Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 04: Asia Pacific Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 05: Asia Pacific Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 06: Asia Pacific Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 07: Asia Pacific Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 08: Asia Pacific Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 09: Asia Pacific Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 10: Asia Pacific Industry Value (US$ Mn) Analysis, by Country, 2018 to 2023
Table 11: Asia Pacific Industry Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 12: Asia Pacific Industry Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 13: India Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 14: India Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 15: India Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 16: India Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 17: India Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 18: India Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 19: India Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 20: India Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 21: India Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 22: Singapore Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 23: Singapore Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 24: Singapore Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 25: Singapore Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 26: Singapore Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 27: Singapore Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 28: Singapore Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 29: Singapore Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 30: Singapore Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 31: Japan Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 32: Japan Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 33: Japan Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 34: Japan Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 35: Japan Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 36: Japan Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 37: Japan Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 38: Japan Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 39: Japan Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 40: China Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 41: China Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 42: China Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 43: China Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 44: China Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 45: China Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 46: China Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 47: China Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 48: China Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 49: Australia & New Zealand Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 50: Australia & New Zealand Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 51: Australia & New Zealand Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 52: Australia & New Zealand Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 53: Australia & New Zealand Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 54: Australia & New Zealand Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 55: Australia & New Zealand Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 56: Australia & New Zealand Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 57: Australia & New Zealand Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 58: South Korea Industry Value (US$ Mn) Analysis, by Type, 2018 to 2023
Table 59: South Korea Industry Value (US$ Mn) Analysis, by Type, 2024 to 2034
Table 60: South Korea Industry Value (US$ Mn) Opportunity Analysis, by Type, 2024 to 2034
Table 61: South Korea Industry Value (US$ Mn) Analysis, by Treatment Type, 2018 to 2023
Table 62: South Korea Industry Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 63: South Korea Industry Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 64: South Korea Industry Value (US$ Mn) Analysis, by End User, 2018 to 2023
Table 65: South Korea Industry Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 66: South Korea Industry Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Asia Pacific Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 02: Asia Pacific Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Asia Pacific Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 04: Asia Pacific Industry Incremental $ Opportunity, 2024 to 2034
Figure 05: Asia Pacific Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 06: Asia Pacific Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 07: Asia Pacific Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 08: Asia Pacific Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 09: Asia Pacific Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 10: Asia Pacific Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 11: Asia Pacific Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 12: Asia Pacific Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 13: Asia Pacific Industry Attractiveness Analysis by End User, 2024 to 2034
Figure 14: Asia Pacific Industry Share and BPS Analysis by Country, 2024 & 2034
Figure 15: Asia Pacific Industry Y-o-Y Growth Projections by Country, 2024 to 2034
Figure 16: Asia Pacific Industry Attractiveness Analysis by Country, 2024 to 2034
Figure 17: India Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 18: India Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: India Industry Value Y-o-Y Growth and Forecast, 2034
Figure 20: India Industry Incremental $ Opportunity, 2024 to 2034
Figure 21: India Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 22: India Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 23: India Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 24: India Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 25: India Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 26: India Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 27: India Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 28: India Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 29: India Industry Attractiveness Analysis by End User, 2024 to 2034
Figure 30: Singapore Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 31: Singapore Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 32: Singapore Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 33: Singapore Industry Incremental $ Opportunity, 2024 to 2034
Figure 34: Singapore Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 35: Singapore Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 36: Singapore Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 37: Singapore Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 38: Singapore Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 39: Singapore Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 40: Singapore Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 41: Singapore Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 42: Singapore Industry Attractiveness Analysis by End User, 2024 to 2034
Figure 43: Japan Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 44: Japan Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 45: Japan Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 46: Japan Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 47: Japan Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 48: Japan Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 49: Japan Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 50: Japan Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 51: Japan Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 52: Japan Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 53: Japan Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 54: Japan Industry Attractiveness Analysis by End User, 2024 to 2034
Figure 55: China Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 56: China Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 57: China Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 58: China Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 59: China Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 60: China Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 61: China Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 62: China Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 63: China Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 64: China Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 65: China Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 66: China Industry Attractiveness Analysis by End User, 2024 to 2034
Figure 67: Australia & New Zealand Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 68: Australia & New Zealand Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 69: Australia & New Zealand Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 70: Australia & New Zealand Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 71: Australia & New Zealand Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 72: Australia & New Zealand Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 73: Australia & New Zealand Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 74: Australia & New Zealand Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 75: Australia & New Zealand Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 76: Australia & New Zealand Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 77: Australia & New Zealand Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 78: Australia & New Zealand Industry Attractiveness Analysis by End User, 2024 to 2034
Figure 79: South Korea Industry Value (US$ Mn) Historical Analysis, 2018 to 2023
Figure 80: South Korea Industry Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 81: South Korea Industry Value Y-o-Y Growth and Forecast, 2018 to 2034
Figure 82: South Korea Industry Share and BPS Analysis by Type, 2024 & 2034
Figure 83: South Korea Industry Y-o-Y Growth Projections by Type, 2024 to 2034
Figure 84: South Korea Industry Attractiveness Analysis by Type, 2024 to 2034
Figure 85: South Korea Industry Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 86: South Korea Industry Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 87: South Korea Industry Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 88: South Korea Industry Share and BPS Analysis by End User, 2024 & 2034
Figure 89: South Korea Industry Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 90: South Korea Industry Attractiveness Analysis by End User, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the expected market value of alopecia treatment solutions in Asia Pacific for 2024?
Revenue from alopecia treatment in Asia Pacific has been calculated at US$ 2.66 billion for 2024.
What is the projected sales value of alopecia treatment solutions by 2034?
Sales of alopecia treatment drugs are predicted to reach US$ 5.03 billion by 2034.
What are the projections for alopecia treatment drugs in Asia Pacific?
Demand for alopecia treatment medications in Asia Pacific is projected to increase at a CAGR of 6.6% from 2024 to 2034.
At what rate is the market predicted to expand in China?
The market in China is forecasted to expand at a CAGR of 5.7% through 2034.
What is the new treatment for alopecia in 2023?
In June 2023, the FDA approved LITFULO® (Ritlecitinib), a new JAK inhibitor, as the first treatment for severe alopecia areata in adults and adolescents aged 12 and above.
Demand and Trend Analysis of Alopecia Treatment in Asia Pacific